L6545
Letrozole
≥98% (HPLC), powder, non-steroidal aromatase inhibitor
동의어(들):
4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile
로그인조직 및 계약 가격 보기
모든 사진(2)
크기 선택
보기 변경
10 MG
₩197,621
50 MG
₩548,100
About This Item
실험식(Hill 표기법):
C17H11N5
CAS Number:
Molecular Weight:
285.30
MDL number:
UNSPSC 코드:
51111800
PubChem Substance ID:
NACRES:
NA.77
추천 제품
제품명
Letrozole, ≥98% (HPLC)
분석
≥98% (HPLC)
양식
powder
색상
white to off-white
solubility
DMSO: >50 mg/mL
주관자
Novartis
저장 온도
2-8°C
SMILES string
N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
InChI
1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
InChI key
HPJKCIUCZWXJDR-UHFFFAOYSA-N
유전자 정보
human ... CYP19A1(1588)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
애플리케이션
Letrozole has been used:
- in organoid growth assay to determine its inhibitory capacity(48)
- to investigate steroid receptor coactivator-1 (SRC-1) mediated endogenous estrogen regulation of hippocampal PSD-95(49)
- to determine its effects on tumor-induced hyperalgesia(50)
- for hormonal manipulation in rats(51)
- to study its effects on lipocalin-2 (Lcn2)(52)
- to determine its effects on mechanical hyperalgesia and aromatase expression(53)
생화학적/생리학적 작용
Letrozole acts as an adjuvant agent and is used to treat breast cancer.[1]
Letrozole is a non-steroidal aromatase inhibitor.
Letrozole is a third generation nonsteroidal aromatase inhibitor. It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.
특징 및 장점
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Repr. 2 - STOT RE 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
시험 성적서(COA)
Lot/Batch Number
이미 열람한 고객
Drugs for Pregnant and Lactating Women E-Book (2009)
Bianca Posocco et al.
PloS one, 15(2), e0228822-e0228822 (2020-02-08)
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice
Natalia Lagunas et al.
Frontiers in neuroanatomy, 16, 902218-902218 (2022-07-12)
Sex steroid hormones, such as androgens and estrogens, are known to exert organizational action at perinatal periods and activational effects during adulthood on the brain and peripheral tissues. These organizational effects are essential for the establishment of biological axes responsible
Dennis C Sgroi et al.
Journal of the National Cancer Institute, 105(14), 1036-1042 (2013-07-03)
Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)-positive breast cancer are limited. The HOXB13/IL17BR (H/I) biomarker predicts recurrence risk in ER-positive, lymph node-negative breast cancer patients. H/I was evaluated in MA.17 trial for prognostic performance
Rob Riemsma et al.
Current medical research and opinion, 28(8), 1263-1279 (2012-06-29)
Third-generation aromatase inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced breast cancer compared with tamoxifen. For HR+, HER2+ MBC, combination of an AI with an anti-HER2 agent (lapatinib or trastuzumab) has shown clinical benefit. Six databases were
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
